164 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal http://www.zacks.com/stock/news/292909/the-zacks-analyst-blog-highlights-nordisk-tjx-cigna-regeneron-and-arcelormittal?cid=CS-ZC-FT-292909 Feb 20, 2018 - The Zacks Analyst Blog Highlights: Nordisk, TJX, Cigna, Regeneron and ArcelorMittal
Eurozone Beats United States Again: 5 Hot Stock Picks http://www.zacks.com/stock/news/293079/eurozone-beats-united-states-again-5-hot-stock-picks?cid=CS-ZC-FT-293079 Feb 21, 2018 - 5 Europe-based stocks to buy as the region scores decade-high growth rate in 2017.
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm http://www.zacks.com/stock/news/293455/pharma-stock-roundup-azns-imfinzi-gets-2nd-fda-nod-mrk-to-buy-australian-firm?cid=CS-ZC-FT-293455 Feb 23, 2018 - Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
Pfizer Gets Mixed Feedback on Cancer Treatments From CHMP http://www.zacks.com/stock/news/293908/pfizer-gets-mixed-feedback-on-cancer-treatments-from-chmp?cid=CS-ZC-FT-293908 Feb 27, 2018 - CHMP recommends in favor of two hematology medicines of Pfizer (PFE) while recommending against label expansion of kidney cancer drug, Sutent.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio http://www.zacks.com/stock/news/294071/4-buy-ranked-large-cap-pharma-stocks-to-boost-your-portfolio?cid=CS-ZC-FT-294071 Feb 28, 2018 - Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
M&A, Innovation & New Drugs to Drive Pharma Stocks http://www.zacks.com/commentary/152408/ma-innovation-new-drugs-to-drive-pharma-stocks?cid=CS-ZC--152408 Mar 08, 2018 - M&A, Innovation & New Drugs to Drive Pharma Stocks
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns http://www.zacks.com/stock/news/295726/diabetes-devices-market-on-a-tear-3-stocks-for-solid-returns?cid=CS-ZC-FT-295726 Mar 15, 2018 - Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Novo Nordisk Obtains Licence for Sickle Cell Disease Program http://www.zacks.com/stock/news/298364/novo-nordisk-obtains-licence-for-sickle-cell-disease-program?cid=CS-ZC-FT-298364 Apr 06, 2018 - Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss http://www.zacks.com/stock/news/301962/novo-nordisk-nvo-beats-q1-earnings-estimates-sales-miss?cid=CS-ZC-FT-301962 May 02, 2018 - Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff http://www.zacks.com/stock/news/323818/novo-nordisk-to-restructure-rd-unit-lay-off-400-staff?cid=CS-ZC-FT-323818 Sep 19, 2018 - Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

Pages: 1...1011121314151617

<<<Page 15>